EZH2 overexpression promotes tumorigenesis in mouse models of lung cancer9 and has been linked to poor clinical outcomes in patients with non-small cell lung cancer (NSCLC), as well as other types of carcinomas10–16. The gene discussed is EZH2; the disease is non-small cell lung carcinoma.